Group 1 - The core viewpoint of the news is the successful re-election of the Microcirculation Medication Professional Committee of the China Traditional Chinese Medicine Association, which aims to enhance the development and application of microcirculation in traditional Chinese medicine [1][5] - The second term work plan includes four main areas: promoting collaborative innovation, deepening research and application of traditional Chinese medicine, academic dissemination and brand building, and policy research and industry standards [1][8] - The new committee consists of 215 members, with Professor Wang Xiaolong elected as the new chairman and 32 vice-chairmen elected from various institutions [7] Group 2 - The first committee's work was summarized, highlighting the close relationship between microcirculation and various diseases, and the need for interdisciplinary collaboration [3] - The newly elected committee's management regulations were announced, clarifying its nature, business scope, member management, organizational structure, and financial management [7] - The emphasis on the importance of microcirculation research in the inheritance and innovation of traditional Chinese medicine was reiterated, along with expectations for the new committee to focus on disease prevention and treatment challenges [8]

Core Insights - The article highlights a significant increase in respiratory diseases, particularly COVID-19, during the transition from spring to summer, with a notable rise in positive testing rates across various regions in China [1][3]. Group 1: Respiratory Disease Trends - The positivity rate for COVID-19 testing has been on the rise since April, with southern provinces showing a notably higher rate compared to northern ones. The proportion of COVID-19 cases among outpatient flu-like cases increased from 7.5% to 16.2% [1]. - Among adults aged 15 and older, COVID-19 positivity rates are the highest in both outpatient and inpatient cases. The rate of COVID-19 in severe acute respiratory infection cases rose from 3.3% to 6.3% [1]. Group 2: Causes and Transmission - Respiratory infectious diseases are caused by pathogens entering through the respiratory tract, with common pathogens including viruses and bacteria. The fluctuation in temperature and increased humidity in May contribute to a higher survival rate of viruses [3][4]. - The transmission of respiratory diseases occurs through various means, including droplet transmission, airborne transmission, and contact transmission [5][6][7]. Group 3: Prevention Measures - Emphasis is placed on personal hygiene, such as frequent handwashing, especially after contact with public facilities, to reduce the risk of virus transmission [8][9]. - It is recommended to ensure proper indoor air circulation by ventilating spaces at least three times a day for a minimum of 15 minutes to lower indoor virus concentrations [10]. - The article discusses the use of traditional Chinese medicine, specifically the Xia Sang Ju granules, which have shown potential in inhibiting flu and coronavirus, supported by multiple patents for their effective components [12][18].

2025年05月15日，特一药业2024年度网上业绩说明会在全景网顺利举行。出席本次业绩说明会的人员有 董事长、总经理许丹青、副董事长、副总经理许松青、董事、副总经理、财务总监、董事会秘书陈习 良、董事卢北京、独立董事赵晓波、独立董事赖瀚琪、保荐代表人郭彬。 根据全景数据后台统计，在今天的交流过程中，来自全国多个省、市地区的投资者共向上市公司提问39 个，公司嘉宾共回答问题39个，答复率100.00%，充分实现了上市公司与投资者的良好互动。 以下为业绩说明会问答实录： 1、问：许董好:特一属家族企业，对于企业的公司治理、产品创新、长远发展都存在诸多掣肘。2024年 净利润让投资者大跌眼镜、大失所望。2025年您会采取哪些有力措施:改革股权结构、提升特一经营业 绩谢谢。【征集问题】 回答：您好，感谢您对公司的关注！2024年，公司围绕"打基础、利长远"进行营销组织变革，对原有的 组织架构和营销渠道进行优化和调整，在药店销售方面逐步由经销商模式调整为自营+推广服务商的混 合模式。由于营销组织变革和营销模式的调整，涉及到销售渠道的衔接和药店销售业务的交接，在这个 过程中，为了保证变革的顺利推进，公司减少了核心产品止 ...

股票代码：002788 股票简称：鹭燕医药 鹭燕医药股份有限公司投资者关系活动记录表 编号：2025-002 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 活动参与人员 线上参与厦门辖区上市公司 2024 年年报业绩说明会暨 投资者网上集体接待日的投资者 时间 2025 年 05 月 15 日（星期四）下午 15:40-17:00 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 形式 网络远程交流 上市公司接待人员 姓名 董事长兼总经理：吴金祥先生 独立董事：叶少琴女士 财务总监：曾铮女士 董事会秘书：叶泉青先生 交流内容及具体问 答记录 1、公司今年有几个项目可以投产，对利润有多少影响？ 答：公司 2025 年的具体经营规划，敬请查阅公司 2024 年年报第三节"管理层讨论与分析"第十一项"公司未 来发展的展望"第（二）点"2025 年经营计划"。谢谢 您对公司的关注与支持。 2、吴总您好：非常看好鹭燕医药，感觉今年是鹭燕非常 关键的一年，鹭燕今年主要的突破方向有哪些呢？ 答 ...

Group 1: Health Consumption Promotion - The Ministry of Commerce and the National Health Commission, along with 12 other departments, have jointly issued a plan to promote health consumption, focusing on ten key tasks such as enhancing healthy dietary consumption and optimizing the market supply of special foods [1] - The health consumption market is expanding as public awareness of health increases, with new business models and scenarios emerging, making health consumption a new growth point for boosting overall consumption [1] Group 2: Traditional Chinese Medicine (TCM) Night Market - The TCM cultural night market in Jiangxi has become a vibrant venue, attracting young people to experience TCM through various activities such as making herbal sachets and tasting medicinal cuisine [2][3] - The night market features 150 stalls and nine exhibition areas, promoting TCM culture while meeting public demand for health and wellness [3][4] Group 3: Fitness and Sports Consumption - The "Jinling Matrix" sports complex in Nanjing offers diverse fitness activities, transforming traditional parks into multi-functional consumption spaces that combine sports, leisure, and commerce [6][7] - The integration of sports and tourism in urban parks is redefining outdoor exercise, providing comprehensive service experiences and promoting a healthy lifestyle among city residents [8] Group 4: Health Tourism and Wellness - The "Kangyang Town" in Yunnan, known for its abundant Dendrobium, has become a health tourism destination, attracting visitors with its unique offerings such as Dendrobium cuisine and traditional medical services [9][10] - The local government plans to develop new business models around health tourism, enhancing the brand's visibility and integrating various health and wellness services [11][12]

编号：2025-004 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活 | 媒体采访  业绩说明会 | | 动类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 | | | 活动参与人员 通过"全景路演"(http://rs.p5w.net)参与业绩说明会的投资者 | | 上市公司接待 | 董事长、总经理：许丹青 | | | 副董事长、副总经理：许松青 | | | 董事、副总经理、财务总监、董事会秘书：陈习良 | | | 董事：卢北京 | | 人员 | 独立董事：赵晓波 | | | 独立董事：赖瀚琪 | | | 东莞证券保荐代表人：郭彬 | | 时间 | 2025 年 5 月 15 日 | | 地点 | "全景路演"(http://rs.p5w.net) | | 形式 | 线上文字交流 | | 交流内容及具 | 一、特一微信公众号和年报都把"止咳宝"产品看作企业的核心命脉。请问 回复：您好，感谢您对公司的关注！公司将核心品种止咳宝片的销售增长作 | | | 许董：难道管理层相信就靠一个止咳宝把整个特一支撑起来吗？就这样不用再努 | | | ...

Core Points - The China Traditional Chinese Medicine Association (CTCMA) aims to serve the TCM industry and has over 900 member enterprises and 67 branches, gathering more than 10,000 experts in the field [1][3] - The second term of the Microcirculation Medication Professional Committee was inaugurated on May 10, 2025, in Zhengzhou, marking a new beginning for the committee [1][3] - The new committee plans to focus on collaborative innovation, deepening TCM research, academic dissemination, and policy research to enhance the quality of TCM development [15][18] Summary of Key Sections Inauguration and Leadership - The second term of the Microcirculation Medication Professional Committee was successfully held with over 160 attendees, including experts and representatives from various institutions [1][3] - Wang Xiaolong from Shanghai University of Traditional Chinese Medicine was elected as the new chairman, with 215 new committee members elected [10][8] Achievements of the First Committee - The first committee achieved significant results in organizational development, academic exchange, and public health awareness, including hosting four "Craftsman National Medicine Innovation Development Conferences" and reaching over 100,000 online viewers [5][12] - The committee also provided a platform for over 1,000 specialists through evidence-based TCM research lectures [5] Future Work Plan - The second committee's five-year work plan includes promoting collaborative innovation, enhancing TCM research and application, academic dissemination, and policy research [15][18] - The committee aims to accumulate scientific evidence for the application of TCM products in microcirculation and improve clinical efficacy and patient quality of life [15][18] Emphasis on Party Building - The association emphasized the importance of party building in guiding the committee's work and ensuring compliance with national laws and regulations [12][19] - The committee plans to strengthen its activities and improve the quality of its operations in alignment with the association's goals [17][19]

齐鲁晚报·齐鲁壹点 通讯员 杜永武 5月13日，由北京大学全球健康发展研究院主办，北大科技园博雅大讲堂、北大图书馆协办的"价值为 纲：医药产业的价值重构之生命的中医药思考"主题活动在北京大学科技园北领讲堂举行，来自医药行 业、科技行业、制造业等众多行业的企业家、北京大学本硕博学生等各界友人近200人参加活动。鲁南 制药集团党委书记、董事长、总经理张贵民发表主题演讲。 张贵民在主题演讲中提出，企业的根本价值在于为社会提供优质产品与服务，新价值论强调企业应 以"价值创造"为核心，"谁能给企业创造价值，谁就是企业的主人"，突出"人"作为贡献者在企业发展中 的核心地位，打破传统股权结构衡量企业价值的局限。 围绕中医药发展，张贵民从生命与哲学高度阐述观点，强调中医药"天人合一"的整体观，其核心在于调 节人体达到平衡，最大优势是"治未病"。以鲁南制药基于"荆防败毒散"研发荆防颗粒，在疫情中展现干 预价值为例，印证中医药的实践意义。 张贵民强调，中医药必须与现代科技结合，如鲁南制药中药提取车间数字化率达95%，实现全流程自动 化；同时要加强循证医学研究，建立客观疗效评价体系。发展方向上需"守正创新"，传承经典古方结合 现代 ...

Core Insights - The article highlights the modernization and standardization of the traditional Chinese medicine (TCM) industry, emphasizing the collaboration between Guoshengtang and Huawei to innovate in TCM services through AI and digital infrastructure [1][21] - Guoshengtang reported a revenue of 30.22 billion yuan for 2024, marking a 30.1% year-on-year increase, alongside a net profit growth of over 30% [1][4][21] Financial Performance - The company achieved a record revenue of 30.22 billion yuan in 2024, with a 30.1% increase compared to the previous year [4] - The medical health solutions segment accounted for 98.9% of total revenue, reaching 29.88 billion yuan, growing by 30.6% [4] - Adjusted net profit reached 4 billion yuan, a 31.4% increase year-on-year, with an adjusted net profit margin of 13.2% [5] Strategic Expansion - Guoshengtang is expanding its service network both nationally and internationally, adding 21 new stores through self-construction and acquisitions, bringing the total to 79 stores across 20 cities in China and Singapore [9][12] - The company plans to enter Southeast Asian markets, including Malaysia and Indonesia, within three years, leveraging its validated domestic model and digital capabilities [12][14] Innovation and Technology - The integration of AI technology is a key focus, with Guoshengtang developing AI-assisted decision-making systems to enhance operational efficiency and patient care [5][17] - The company has introduced new proprietary formulations, expanding its product library to 13, targeting high-demand areas such as oncology and pediatrics [11] Customer Engagement - The company reported a 25.9% increase in patient visits, totaling 5.41 million, with a customer retention rate of 67.1% [10] - Membership revenue grew by 32%, indicating strong customer loyalty and engagement [10] Ecosystem Development - Guoshengtang is enhancing its medical ecosystem by collaborating with public hospitals and TCM universities to improve resource allocation and service delivery [16] - The company is also focusing on building a digital TCM model, utilizing AI to improve treatment efficiency and patient outcomes [17][18]

Core Viewpoint - The article highlights the transformation of Dong'a County into a leading health and wellness hub, leveraging its rich heritage in traditional Chinese medicine, particularly the production of Ejiao, to create a comprehensive health industry ecosystem [1][7]. Group 1: Brand Development and Recognition - Dong'a County's "Kangyang Dong'a" brand was awarded the title of "Most Influential Brand in Shandong," showcasing its commitment to health and wellness [1]. - The county has established a cultural and industrial integration model, promoting the Ejiao industry as a key economic pillar [2][3]. Group 2: Cultural and Historical Significance - Ejiao, known as a "national treasure" and "blood-nourishing holy medicine," has a history of over 3,000 years, deeply rooted in the local culture and economy [1][2]. - The county has organized extensive research on Ejiao, compiling over 3,200 ancient recipes and traditional practices, which have been recognized in cultural research awards [2]. Group 3: Innovation and Modernization - Dong'a County is innovating within the Ejiao industry by integrating culture, tourism, and health, transitioning from traditional manufacturing to a multi-faceted industry model [2][4]. - The establishment of various cultural experience platforms and the creation of a national-level Ejiao museum reflect the county's efforts to modernize and promote its traditional practices [3][4]. Group 4: Economic Growth and Future Plans - In 2024, the county's health industry is projected to see significant growth, with industrial output, revenue, and profits expected to increase by 18%, 19%, and 27% respectively [7]. - Dong'a County aims to enhance its competitive advantages and develop a diverse health industry ecosystem, contributing to the "Healthy China" initiative [7].